Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by Citigroup
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Citigroup from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $129.00 price target on the biotechnology company’s stock, up from their previous price target of $83.00. Citigroup’s […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Citigroup from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $129.00 price target on the biotechnology company’s stock, up from their previous price target of $83.00. Citigroup’s […]
